Compare ERO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERO | BEAM |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2021 | 2019 |
| Metric | ERO | BEAM |
|---|---|---|
| Price | $25.06 | $22.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $37.50 | ★ $52.21 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 03-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $53.59 | N/A |
| Revenue Next Year | N/A | $39.64 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $9.30 | $13.53 |
| 52 Week High | $39.80 | $36.44 |
| Indicator | ERO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 33.18 |
| Support Level | $23.01 | $20.23 |
| Resistance Level | $26.77 | $23.42 |
| Average True Range (ATR) | 1.11 | 1.31 |
| MACD | -0.12 | -0.29 |
| Stochastic Oscillator | 38.24 | 1.75 |
Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.